Practical Aspects of Incorporating CAR T-Cell Therapy into Your Practice
This activity is not certified for credit
Release Date: September 9, 2021
Expiration Date: September 9, 2022
Jointly provided by Postgraduate Institute for Medicine and Bio Ascend, LLC
Activity Overview
Hear from 3 renowned experts actively engaged in the care of patients with lymphoma and multiple myeloma from an independent satellite symposium that took place following the #ASCO21 Meeting.
Target Audience
The target audience for this activity is community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma.
Learning Objectives
After participating in this activity, participants should be better able to:
- Incorporate CAR T cell therapy into their clinical practice and identify appropriate patients
- Develop strategies to mitigate treatment-related adverse events that may occur during treatment with CAR T cell therapy
- Discuss the emerging results of clinical trials that are investigating CAR T cell therapies in lymphoma and myeloma
- Optimize the referral process and multidisciplinary care for patients who qualify for CAR T Cell therapy
Method of Participation
There are no fees for participating in this activity
Topics Presented
--Overview of CAR T-cell therapy
--CAR T-cell mechanism of action
--Treatment process
--CD19-targeting
--BCMA-targeting
How to manage novel AE profile
--Cytokine release syndrome
--Neurotoxicity
Practical aspects of CAR T Cell therapy
--Choosing the right patient for CAR T Cell therapy
--Optimizing the referral process and multidisciplinary care
Panel Discussion and Q&A
Chair
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Consultant Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC., Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis
Faculty
Loretta Nastoupil, MD
Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Director, Lymphoma Outcomes Database, Department of Lymphoma/Myeloma, Division of Cancer Medicine
Section Chief, New Drug Development, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Fees: Celgene, Genentech, Gilead/Kite, Janssen, Novartis, Pfizer Inc., Takeda Pharmaceutical Company, TG Therapeutics
Contracted Research: Celgene, Epizyme, Inc., Genentech, Gilead/Kite, Janssen, Merck & Co., Novartis, Pfizer Inc., Takeda Pharmaceutical Company
Nina Shah, MD
Associate Professor, Department of Medicine
University of California San Francisco
San Francisco, California
Consulting Fees: Amgen Inc., CareDx, GlaxoSmithKline LLC, Indapta Therapeutics, Karyopharm Therapeutics, Kite Pharma, Oncopeptides, Sanofi
Contracted Research: Bluebird Bio, Celgene/BMS, Janssen, Nektar Therapeutics, Poseida Therapeutics, Inc., Sutra Biopharma, Teneobio
Disclosure of Commercial Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. The existence or absence of COI for everyone in a position to control educational content will be disclosed to participants prior to the start of each activity.
Support
This activity is supported by independent educational grants from Janssen Scientific Affairs, LLC., and Legend Biotech.
Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.